{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T23:15:06Z","timestamp":1786403706320,"version":"build-2736575974"},"reference-count":27,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Multiple myeloma (MM) is a heterogeneous disease that may be evaluated by a broad array of imaging and laboratory techniques to measure disease activity and predict prognosis. Fluorodeoxyglucose (FDG) positron emission tomography\/computed tomography (PET\/CT) scanning has been shown to be predictive of patient outcomes throughout the disease course. We sought to corroborate these findings by examining the prognostic impact of PET\/CT scanning in the posttransplant setting. We retrospectively analyzed PET\/CT scans in 229 MM patients receiving an autologous stem cell transplant (ASCT) near day 100, and correlated these findings with time to progression(TTP) and overall survival (OS) to assess the impact of day 100 PET\/CT scan findings as an independent prognostic factor. The median OS for the entire cohort was 61.5 months (95% confidence interval [CI], 49-75) and the median TTP was 18.5 months (95% CI, 15.4-21.8). Among patients with abnormal day 100 PET findings (PET+), median TTP was 12.4 months vs 24 months among those with normal PET findings (PET\u2212) (P &amp;lt; .0001). The median OS in the PET+ group was 46 months compared with 99 months in the PET\u2212 group (P &amp;lt; .0001). We conclude that an abnormal PET\/CT scan near day 100 post-ASCT is predictive of shorter TTP and OS, with prognostic significance retained after adjusting for disease response and other prognostic variables in MM.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020004131","type":"journal-article","created":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T05:04:31Z","timestamp":1625893471000},"page":"2753-2759","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":21,"title":["Prognostic impact of posttransplant FDG PET\/CT scan in multiple myeloma"],"prefix":"10.1182","volume":"5","author":[{"given":"Marcella","family":"Kaddoura","sequence":"first","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-0203","authenticated-orcid":false,"given":"Francis K.","family":"Buadi","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1193-1559","authenticated-orcid":false,"given":"Martha Q.","family":"Lacy","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Hwa","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9488-8212","authenticated-orcid":false,"given":"Amie","family":"Fonder","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Hobbs","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hayman","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lust","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-1411","authenticated-orcid":false,"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Gonsalves","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-9434","authenticated-orcid":false,"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5391-9537","authenticated-orcid":false,"given":"Stephen M.","family":"Broski","sequence":"additional","affiliation":[{"name":"Department of Radiology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"Division of Hematology,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,7,9]]},"reference":[{"issue":"1","key":"2021070922552004200_B1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat Commun."},{"issue":"12","key":"2021070922552004200_B2","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1038\/s41375-018-0037-9","article-title":"Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups","volume":"32","author":"Bolli","year":"2018","journal-title":"Leukemia."},{"issue":"12","key":"2021070922552004200_B3","doi-asserted-by":"crossref","first-page":"e515","DOI":"10.1016\/j.clml.2018.06.028","article-title":"Nonsecretory and light chain escape in patients with multiple myeloma","volume":"18","author":"Patel","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"2021070922552004200_B4","doi-asserted-by":"crossref","first-page":"7583","DOI":"10.2147\/OTT.S122241","article-title":"Non-secretory multiple myeloma: from biology to clinical management","volume":"9","author":"Dupuis","year":"2016","journal-title":"OncoTargets Ther."},{"issue":"8","key":"2021070922552004200_B5","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"issue":"9","key":"2021070922552004200_B6","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia."},{"issue":"9","key":"2021070922552004200_B7","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/leu.2009.89","article-title":"International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia."},{"issue":"10","key":"2021070922552004200_B8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41408-018-0124-1","article-title":"Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group","volume":"8","author":"Moulopoulos","year":"2018","journal-title":"Blood Cancer J."},{"issue":"2","key":"2021070922552004200_B9","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1038\/bcj.2017.14","article-title":"Discrepancies between the percentage of plasma cells in bone marrow aspiration and BM biopsy: impact on the revised IMWG diagnostic criteria of multiple myeloma","volume":"7","author":"Lee","year":"2017","journal-title":"Blood Cancer J."},{"issue":"21","key":"2021070922552004200_B10","first-page":"3141","article-title":"Incidence and survival outcomes of extramedullary myeloma","volume":"122","author":"Ghimire","year":"2013","journal-title":"Blood."},{"issue":"3","key":"2021070922552004200_B11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cpet.2019.03.005","article-title":"Fluorodeoxyglucose-PET\/computed tomography as a predictor of prognosis in multiple myeloma","volume":"14","author":"Nanni","year":"2019","journal-title":"PET Clin."},{"issue":"6","key":"2021070922552004200_B12","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1007\/s00259-011-1738-8","article-title":"Value of 18F-fluorodeoxyglucose uptake in positron emission tomography\/computed tomography in predicting survival in multiple myeloma","volume":"38","author":"Haznedar","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"2","key":"2021070922552004200_B13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.20.00386","article-title":"Standardization of 18F-FDG\u2013PET\/CT according to Deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma","volume":"39","author":"Zamagni","year":"2021","journal-title":"J Clin Oncol."},{"issue":"10","key":"2021070922552004200_B14","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"Bartel","year":"2009","journal-title":"Blood."},{"issue":"19","key":"2021070922552004200_B15","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1158\/1078-0432.CCR-15-0396","article-title":"PET\/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma","volume":"21","author":"Zamagni","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"23","key":"2021070922552004200_B16","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood."},{"issue":"25","key":"2021070922552004200_B17","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","article-title":"Prospective evaluation of magnetic resonance imaging and [(18)F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: results of the IMAJEM study","volume":"35","author":"Moreau","year":"2017","journal-title":"J Clin Oncol."},{"key":"2021070922552004200_B18","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun."},{"issue":"1","key":"2021070922552004200_B19","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3324\/haematol.10554","article-title":"A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma","volume":"92","author":"Zamagni","year":"2007","journal-title":"Haematologica."},{"issue":"6","key":"2021070922552004200_B20","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.bbmt.2015.03.001","article-title":"The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation","volume":"21","author":"Patriarca","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"issue":"3","key":"2021070922552004200_B21","doi-asserted-by":"crossref","first-page":"514","DOI":"10.2214\/AJR.18.20989","article-title":"Comparison of whole-body DWI and (18)F-FDG PET\/CT for detecting intramedullary and extramedullary lesions in multiple myeloma","volume":"213","author":"Chen","year":"2019","journal-title":"AJR Am J Roentgenol."},{"issue":"3","key":"2021070922552004200_B22","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1148\/radiol.13131529","article-title":"Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma","volume":"271","author":"Giles","year":"2014","journal-title":"Radiology."},{"key":"2021070922552004200_B23","doi-asserted-by":"crossref","first-page":"109403","DOI":"10.1016\/j.ejrad.2020.109403","article-title":"The utility of ADC value in diffusion-weighted whole-body MRI in the follow-up of patients with multiple myeloma. Correlation study with 18F-FDG PET-CT","volume":"133","author":"Paternain","year":"2020","journal-title":"Eur J Radiol."},{"issue":"1","key":"2021070922552004200_B24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2214\/AJR.11.8185","article-title":"Assessing the relation between bone marrow signal intensity and apparent diffusion coefficient in diffusion-weighted MRI","volume":"200","author":"Padhani","year":"2013","journal-title":"AJR Am J Roentgenol."},{"issue":"1081","key":"2021070922552004200_B25","doi-asserted-by":"crossref","first-page":"20170577","DOI":"10.1259\/bjr.20170577","article-title":"UK quantitative WB-DWI technical workgroup: consensus meeting recommendations on optimisation, quality control, processing and analysis of quantitative whole-body diffusion-weighted imaging for cancer","volume":"91","author":"Barnes","year":"2018","journal-title":"Br J Radiol."},{"issue":"1","key":"2021070922552004200_B26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1148\/radiol.2019181949","article-title":"Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS)","volume":"291","author":"Messiou","year":"2019","journal-title":"Radiology."},{"issue":"7","key":"2021070922552004200_B27","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood-2018-08-825356","article-title":"Imaging in multiple myeloma: how? when?","volume":"133","author":"Zamagni","year":"2019","journal-title":"Blood."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/13\/2753\/1813592\/advancesadv2020004131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/13\/2753\/1813592\/advancesadv2020004131.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T05:04:54Z","timestamp":1625893494000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/13\/2753\/476322\/Prognostic-impact-of-posttransplant-FDG-PET-CT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,9]]},"references-count":27,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2021,7,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020004131","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,9]]}}}